Outcomes in Patients with Rheumatoid Arthritis and Myocardial Infarction



      Patients with rheumatoid arthritis have an increased risk for accelerated atherosclerosis. It is unknown, however, whether rheumatoid arthritis also increases in-hospital mortality after a myocardial infarction or influences the therapy patients receive.


      A cross-sectional analysis of 1,112,676 patients with myocardial infarction in the 2003-2005 Nationwide Inpatient Sample was performed.


      Patients with rheumatoid arthritis were 39% more likely to receive medical therapy (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.30-1.49) than interventional therapy. By using logistic regression, we adjusted for confounding variables to determine the effect of rheumatoid arthritis on the selection of therapy and found that rheumatoid arthritis itself was associated with a 38% increased likelihood of undergoing thrombolysis (OR, 1.38; 95% CI, 1.10-1.71) and a 27% increased likelihood of undergoing percutaneous coronary intervention (OR, 1.27; 95% CI, 1.17-1.39). For the primary outcome measure, we determined that patients with rheumatoid arthritis overall had a 24% better in-hospital mortality compared with other patients with a myocardial infarction (OR, 0.76; 95% CI, 0.68-0.86), which was 34% better after adjusting for confounding variables (OR, 0.66; 95% CI, 0.59-0.74). This better in-hospital mortality was seen in patients with rheumatoid arthritis undergoing medical therapy (adjusted OR, 0.67; 95% CI, 0.59-0.75) and percutaneous coronary intervention (adjusted OR, 0.47; 95% CI, 0.32-0.70), but not in patients undergoing thrombolysis or coronary artery bypass grafting.


      Among patients with myocardial infarction, rheumatoid arthritis was associated with an increased use of thrombolysis and percutaneous coronary intervention. Moreover, patients with rheumatoid arthritis had an in-hospital survival advantage, particularly those undergoing medical therapy and percutaneous coronary intervention.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shoenfeld Y.
        • Gerli R.
        • Doria A.
        • et al.
        Accelerated atherosclerosis in autoimmune rheumatic diseases.
        Circulation. 2005; 112: 3337-3347
        • Solomon D.H.
        • Karlson E.W.
        • Rimm E.B.
        • et al.
        Cardiovascular mortality and morbidity in women diagnosed with rheumatoid arthritis.
        Circulation. 2003; 107: 1303-1307
        • Van Doornum S.
        • McColl G.
        • Wicks I.P.
        Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?.
        Arthritis Rheum. 2002; 46: 862-873
        • Kaplan M.J.
        • McCune W.J.
        New evidence for vascular disease in patients with early rheumatoid arthritis.
        Lancet. 2003; 361: 1068-1069
        • McGettigan P.
        • Henry D.
        Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
        JAMA. 2006; 296: 1633-1644
        • Raza K.
        • Banks M.
        • Kitas G.D.
        Reversing myocardial microvascular disease in a patient with rheumatoid arthritis.
        J Rheumatol. 2005; 32: 754-756
        • Davis 3rd, J.M.
        • Roger V.L.
        • Crowson C.S.
        • et al.
        The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population.
        Arthritis Rheum. 2008; 58: 2603-2611
        • Van Doornum S.
        • Brand C.
        • King B.
        • Sundararajan V.
        Increased case fatality rates following a first myocardial event in patients with rheumatoid arthritis.
        Arthritis Rheum. 2006; 54: 2061-2068
        • Quan H.
        • Li B.
        • Saunders L.D.
        • et al.
        • IMECCHI Investigators
        Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in unique dually coded database.
        Health Serv Res. 2008; 43: 1424-1441
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613
        • Elixhauser A.
        • Steiner C.
        • Harris D.R.
        • Coffey R.M.
        Comorbidity measures for use with administrative data.
        Med Care. 1998; 36: 8-27
        • Rudominer R.L.
        • Roman M.J.
        • Devereux R.B.
        • et al.
        Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction.
        Arthritis Rheum. 2009; 60: 22-29
        • Crowson C.S.
        • Nicola P.J.
        • Kremers H.M.
        • et al.
        How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?.
        Arthritis Rheum. 2005; 52: 3039-3044
        • Chung E.S.
        • Packer M.
        • Lo K.H.
        • et al.
        • Anti-TNF Therapy Against Congestive Heart Failure Investigators
        Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.
        Circulation. 2003; 107: 3133-3140
        • Setoguchi S.
        • Schneeweiss S.
        • Avorn J.
        • et al.
        Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.
        Am Heart J. 2008; 156: 336-341